期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗骨质疏松药雷奈酸锶研究进展

抗骨质疏松药雷奈酸锶研究进展
下载PDF
导出
摘要 通过查阅近几年相关文献,综合抗骨质疏松药雷奈酸锶研究多方面资料和最新观点,对其药物特点、实验研究、临床应用分别进行阐述、归纳和评价,说明雷奈酸锶是一种在体内外都具有良好作用的安全、有效的抗骨质疏松药。它主要用于治疗绝经妇女骨质疏松,减小骨折风险,是惟一既刺激骨形成,又抑制骨吸收,具有双重药理作用,且安全性和耐受性良好的治疗骨质疏松的新一代高效药物。 By consulting the literature in recent years, comprehensive information from a variety of sources, and up-to-date view of the antiosteoporosis drug strontium ranelate study.Its drug characteristics, experimental research,clinical applications were elaborate,summarize and evaluate. Explain strontium ranelate is a kind having a good effect of a safe and effective anti-osteoporosis drugs in vivo.It is mainly used for the treatment of post-menopausal women with osteoporosis, to reduce the risk of fractures.It is both stimulating bone formation,and inhibition of bone resorption.It has a dual pharmacological action,and has a good safety and tolerability for the treatment of osteoporosis.It＇s a new generation of highly drugs to treat ostepoprosis.
作者 覃超 彭建强
机构地区 广东医学院附属福田人民医院骨科
出处 《当代医学》 2013年第18期11-13,共3页 Contemporary Medicine
关键词 雷奈酸锶 骨质疏松 骨形成 骨吸收. Strontium ranelate Osteoporosis Bone formation Bone absorption
分类号 R977 [医药卫生—药品]
  • 相关文献

参考文献33

  • 1North American Menopause Society. Msnagement of postmenopausal osteoporosis:Position statement of the North American Menopause Society[J]. Menopause.2002,9(2):84-101.
  • 2马慧萍,贾正平,葛欣,陈克明.骨质疏松症的药物防治研究现状[J].中国药师,2004,7(10):816-818. 被引量：14
  • 3段定红,黄敏丽.阿法骨化醇与活力钙治疗绝经后骨质疏松症各128例的比较[J].中国新药与临床杂志,2003,22(8):468-470. 被引量：5
  • 4Babb A,Carlson WO Vertebral compression fractures:treatment arid evaiuation[J]. S D Meg, 2006,59(8): 545-5,347.
  • 5Silverwood B.Building health bones[J].Paediatr Nuts,2005,15(5):27-29.
  • 6Huselmann H J, Eizzoli R A comprehensive review of reatmente for postmenopauszl osteoporosis [J]. Osteoporos Int, 2003, 14(1 ): 2-12.
  • 7Odvina CV, Zerwekh JE, Eao DS, et al. Severely suppressed one turnover:a potential compLication of alendronate therapy[J]. J Clin Endocrinel Metab, 2005,90(3):1294-1301.
  • 8Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling[J]. J Bone Miner Res,2005,20(2).177-184.
  • 9Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis[J]. N Engl J Med,2007,357(9):905-916.
  • 10Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (7-34) on fractures and bone mineral density in postmenopausal women with osteoporosis[J]. N Engl J Med, 2001, 344(19): :1434-1441.

二级参考文献30

  • 1刘忠厚 马述仕 王石麟 等.现代临床医学丛书 第1版[M].北京:科学出版社,1998.237.
  • 2CHEN M, CHOW SN. Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwan Residents postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study [J]. Clin Endocrinol, 2001,55(2) : 253-258.
  • 3KANIS JA. Osteoporosis. 1st ed [ M]. London: Blackwell Science Publishing House, 1994. 5-7.
  • 4SAISU T, WAKABAYASHI Y, YAMADA K, et al. Effect of low-calcium hemodialysate on bone metabolism [J ]. J Bone Miner Metab, 2000, 18(2):57-62.
  • 5GILLESPIE WJ, HENRY DA, O'CONNELL DL, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis [ DB/OL].Cochrane Database Syst Rev, 2000, (2) : CD000227.
  • 6TANIZAWA T, IMURA K, ISHII Y, et al. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study [J]. Osteoporos Int,1999,9(2) : 163-170.
  • 7ZHAN Z, YAMAMOTO I , MORTIA R. Urinary pyridinoline and deoxypyridinoline as bone metabolic markers in predicting therapeutic effects of estrogen and alfacaleidol in women with osteoporosis[J]. J Bone Miner Metab, 1999,17(2): 113-118.
  • 8GORAI I, CHAKI O, TAGUCHI Y, et al. Early postmenopausal bone loss is prevented by estrogen and partially by lalpha-OH-vita-min D3: therapeutic effects of estrogen and/or lalpha-OH-vitamin D3[J]. Calcif Tissue Int, 1999, 65(1): 16-22.
  • 9Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal woman with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evalu ation (MORE) Investigato
  • 10Lippman ME, Kreuger KA, Eckert S, et al. Indicators of lifetime estrogenexposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study patientsl[ J ]. J Clin Oncol, 2001, 19:3111

共引文献16

当代医学
2013年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部